# US 8,277,806 B2 · Use of trifunctional bispecific and trispecific antibodies for the treatment of malignant ascites

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,806 B2
- Document ID: US8277806B2
- Status: Granted
- Kind: B2
- Application number: 10/378,218
- Filed: 2003-03-03
- Published: 2003-12-04
- Granted: 2012-10-02
- Earliest claimed: 2000-09-04
- Assignees: Trion Pharma GmbH
- Inventors: Horst Lindhofer
- Web page: https://patentgrep.com/patent/US8277806B2

## CPC

- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61P 35/00: Antineoplastic agents
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/30: from tumour cells
- C07K 16/32: against translation products of oncogenes
- A61K 2039/505: {comprising antibodies}
- A61K 2039/5152: {Tumor cells}
- C07K 2317/31: multispecific
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention describes the use of a pharmaceutical preparation containing a trifunctional bispecific and/or trispecific having the following properties: a) binding to a T cell; b) binding to at least an antigen on a tumor cell associated with malignant ascites and/or pleural effusion; c) binding, by its Fc portion (in the case of bispecific antibodies) or by a third specificity (in the case of trispecific antibodies), to Fc receptor-positive cells for the destruction of the tumor cells in the treatment of malignant ascites and/or pleural effusion.

## Claims

### Claim 1

A method for reducing or inhibiting the formation of ascites fluid in a subject, the method consisting of:
(a) providing a subject having malignant ascites, wherein the malignant ascites comprises tumor cells; and
(b) administering to the subject intraperitoneally three or more doses of a pharmaceutical preparation containing trifunctional bispecific antibodies as the sole therapeutically active agents, wherein:
(i) the trifunctional bispecific antibodies comprise:
(1) a first binding arm that binds to a T cell in the subject via CD3;
(2) a second binding arm that binds to EpCAM on a tumor cell associated with malignant ascites in the subject;
(3) an Fc portion that binds to an Fc receptor-positive cell in the subject that comprises an Fcγ receptor I, an Fcγ receptor III, or a combination thereof; and
(4) isotype combination rat-IgG2b/mouse-IgG2a; and
(ii) the administering is in several increasing doses, with the amount of the trifunctional bispecific antibodies present in the second dose being higher than the amount of the trifunctional bispecific antibodies present in the first dose, and the amount of the trifunctional bispecific antibodies present in the third and any subsequent doses being higher than the amount of the trifunctional bispecific antibodies present in the second dose;
thereby reducing or inhibiting the formation of ascites fluid in the subject.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said first dose comprises 1 to 20 μg of the trifunctional bispecific antibodies, said second dose comprises 20 to 100 μg of the trifunctional bispecific antibodies, and said third and any subsequent doses each comprises 100 to 500 μg of the trifunctional bispecific antibodies.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the first dose comprises 5-10 μg of the trifunctional bispecific antibodies.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the second dose comprises 30-60 μg of the trifunctional bispecific antibodies.

### Claim 5 (depends on 2)

The method according to claim 2, wherein the third dose, and any subsequent doses if present, comprises 100-300 μg of the trifunctional bispecific antibodies.

### Claim 6 (depends on 1)

The method according to claim 1, wherein said administering step consists of administering 3 to 8 doses.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the administering step consists of administering 3 to 6 doses.

### Claim 8 (depends on 6)

The method of claim 6, wherein an interval of about 2 to 3 days occurs between each dose.

### Claim 9 (depends on 1)

The method according to claim 1, wherein said trifunctional bispecific antibodies induce tumor-reactive complement-binding antibodies and a humoral immune response in the subject.

### Claim 10 (depends on 1)

The method according to claim 1, wherein binding of said trifunctional bispecific antibodies to the Fc receptor-positive cells induces or enhances Fc receptor-positive cell expression of at least one of CD40, CD80, CD86, ICAM-1, and LFA-3; secretion of a cytokine; or combinations thereof.

### Claim 11 (depends on 10)

The method according to claim 10, wherein said cytokine is selected from the group consisting of IL-1, IL-2, IL-4, IL-6, IL-8, IL-12, INF-γ, and TNF-α.

### Claim 12 (depends on 1)

The method according to claim 1, wherein binding of said trifunctional bispecific antibodies to Fc receptor-positive cells induces or enhances expression of a cytokine, a co-stimulatory antigen, or combinations thereof in the Fc-receptor-positive cell.

### Claim 13

A method for reducing or inhibiting the formation of ascites or pleural effusion fluid, or a combination thereof, in a subject, the method consisting of administering to a subject having malignant ascites, pleural effusion, or a combination thereof comprising tumor cells, three or more doses of a pharmaceutical preparation containing trifunctional bispecific antibodies as the sole therapeutically active ingredients, wherein:
(i) the amount of the trifunctional bispecific antibodies present in the second dose is higher than the amount of the trifunctional bispecific antibodies present in the first dose, and the amount of the trifunctional bispecific antibodies present in the third and any subsequent doses is higher than the amount of the trifunctional bispecific antibodies present in the second dose; and
(ii) the trifunctional bispecific antibodies comprise a first binding arm that binds to a T cell in the subject via CD3, a second binding arm that binds to EpCAM on a tumor cell associated with malignant ascites or pleural effusion in the subject, and an Fc portion that binds to an Fc receptor-positive cell in the subject that comprises an Fcγ receptor I, an Fcγ receptor III, or a combination thereof; and
(iii) the trifunctional bispecific antibodies are from the isotype combination rat-IgG2b/mouse-IgG2a,
thereby reducing or inhibiting the formation of ascites or pleural effusion fluid, or the combination thereof, in the subject.

### Claim 14 (depends on 13)

The method of claim 13, wherein an interval of about 48 to about 72 hours is present between administering each of the three or more doses.
